July 2019—Prelude Corp. presented interim results from its Predict study during a poster presentation at the American Society of Breast Surgeons annual meeting, April 30–May 5, in Dallas (Abstract 581643).
The Predict study evaluates the impact of DCISionRT on clinical management of patients with ductal carcinoma in situ as compared with traditional clinical and pathologic risk factors. Interim analysis of the study, which included approximately 200 DCIS patients, concluded that inclusion of DCISionRT changed 51 percent of radiation therapy recommendations for patients with DCIS. In the DCISionRT low-risk group, 62 percent of patients had a change in their treatment recommendations; in the DCISionRT elevated-risk group, 35 percent of patients had a change in their treatment recommendations. “In all cases, the decision change was statistically significant and the impact did not differ by clinicopathologic group,” according to a PreludeDx press release.
PreludeDx, 888-211-3247